BriaCell closes $4.7M best-efforts equity offering; 1.45M shares at $3.25 each

BriaCell Therapeutics Corp.

Gross proceeds ~$4.7M from sale of 1,449,300 common shares at $3.25/share in a best-efforts offering.
Placement agent ThinkEquity receives 7.5% cash fee and 5-year warrants for 72,465 shares at $4.0625.
Net proceeds to be used for working capital, general corporate purposes, and business advancement.
Offering closed June 2, 2026; shares issued under effective shelf registration statement (Form S-3).

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

BriaCell Therapeutics Corp. entered into Placement Agency Agreement with ThinkEquity LLC valued at $4.71 million (effective 2026-05-31).

Action: entry
Agreement: equity purchase
Counterparty: ThinkEquity LLC
Value: $4.71 million
Effective: 2026-05-31

Exact text from the filing

On May 31, 2026, BriaCell Therapeutics Corp. (the “Company”) entered into a Placement Agency Agreement (the “Agreement”) with ThinkEquity LLC

View on SEC.gov

294 material agreements filed in the last 30 days. Browse all material agreements →

BriaCell Therapeutics Corp. filing history →

Source: SEC EDGAR

accession 0001493152-26-026953

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.